ABSTRACT
Purpose The impact on the labour force, including healthcare services, from the emergence of mental health symptoms after COVID-19 is uncertain. This rapid review examined the impacts on the labour force and healthcare services and costs related to mental health issues following an acute SARS-CoV-2 infection.
Methods We searched Medline, Embase, and PsycInfo in January 2024, conducted forward citation searches in Scopus, and searched reference lists for studies reporting labour force outcomes (among those with mental health symptoms after COVID-19) and mental health services use among people of any age at least 4 weeks after confirmed/suspected SARS-CoV-2 infection. Titles/abstracts required one reviewer to include but two to exclude; we switched to single reviewer screening after 50% of citations were screened. Selection of full texts used two independent reviewers. Data extraction and risk of bias assessments by one reviewer were verified. Studies were sorted into categories based on the population and outcomes, including timing of outcome assessment, and, if suitable, study proportions were pooled using Freeman-Tukey transformation with assessment of heterogeneity using predetermined subgroups.
Results 45 studies were included with 20 reporting labour force and 28 mental healthcare services use outcomes. 60% were rated as high risk of bias, mainly due to difficulty attributing the outcomes to COVID-19 from potential confounding from employment status or mental healthcare services use prior to infection. Studies on labour force outcomes mostly (85%) reported on populations with symptoms after acute infection that was cared for in outpatient/mixed care settings. Among studies reporting mental healthcare use, 50% were among those hospitalized for acute care and 43% assessed outcomes among populations with post-acute or prolonged symptoms.
Across 13 studies (N=3,106), on average 25% (95% CI 14%, 38%) of participants with symptoms after COVID-19 had mental health symptoms and were unable to work for some duration of time. It was difficult to associate inability to work with having any mental health symptom, because studies often focused on one or a couple of symptoms. The proportion of participants unable to work ranged from 4% to 71%, with heterogeneity being very high across studies (I2 >98%) and not explained by subgroup analyses. Most of these studies focused on people infected with pre-Omicron strains. There was scarce data to inform duration of inability to work. For outcomes related to work capacity and productivity, there was conceptual variability between studies and often only single studies reporting on an outcome among a narrowly focused mental health symptom.
On average across 21 studies (N=445,994), 10% (95% CI 6%, 14%) of participants reported seeing a mental healthcare professional of any type (psychiatrist, psychologist, or unspecified). Heterogeneity was very high and not explained after investigation. There was very limited information on the number of sessions attended. Among seven studies, mainly reporting on populations with post-COVID-19 symptoms, participant referrals to mental health services ranged from 4.2% to 45.3% for a variety of types of mental health symptoms including neuropsychology, psychiatric, and psychological. Though at high risk of bias, findings from one large study suggested 1-2% of those hospitalized during their acute infection may be re-hospitalized due to mental health symptoms attributed to COVID-19.
Conclusions A large minority of people (possibly 25%) who experience persisting symptoms after COVID-19 may not be able to work for some period of time because of mental health symptoms. About 10% of people experiencing COVID-19 may have use for mental health care services after the acute phase, though this rate may be most applicable for those hospitalized for COVID-19. A small minority (possibly 1-2%) may require re-hospitalization for mental health issues. There is limited applicability of the results in most cases to populations with post-COVID-19 symptoms rather than more broadly post-COVID-19 or general populations. Overall, this rapid review highlights the variability of measurement, definition of outcomes and difficulty attributing the outcomes to mental health symptoms after COVID-19 infection.
PROSPERO CRD42024504369
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024504369
Funding Statement
This review was funded by and conducted for the Public Health Agency of Canada (PHAC). The contents of this manuscript do not necessarily represent the views of the Government of Canada. Dr. Hartling is supported by a Canada Research Chair in Knowledge Synthesis and Translation. The funding body had no role in the design of the study, nor the collection, analysis, and interpretation of data.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Knowledge Users: Lea Lamp, Erin Collins and Rojiemiahd Edjoc at the Public Health Agency of Canada (PHAC)
Data Availability
The data generated during this study are available within the manuscript or its supplementary files.
